All Stories

  1. Acknowledgement to Reviewers
  2. International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative
  3. Omics-AD—A multimodal biomarker study on cognitive decline and neuropsychiatric symptoms: Design and cohort characteristics
  4. The measurement of agitation in neurocognitive disorders: A systematic review
  5. Plasma biomarkers in neuropsychiatric syndromes: A narrative review
  6. Disentangling the Clinical and Neuroimaging Spectrum of Neuronal α-Synucleinopathies
  7. Acknowledgement to Reviewers
  8. List of reviewers
  9. Atrophy patterns of deep gray matter nuclei in Alzheimer's disease and frontotemporal dementia
  10. The relationships between cerebrospinal fluid neurofilament light chain and hippocampal atrophy with cognitive decline
  11. Leveraging multiomic approaches to elucidate mechanisms of heterogeneity in Alzheimer's disease: Neuropsychiatric symptoms, co‐pathologies, and sex differences
  12. Message From the Editors to Our Reviewers
  13. International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative
  14. APOE -mediated associations of promoter variants of GRIN1 and GRIN2B with behavioral symptoms and age at onset of Alzheimer’s disease dementia
  15. Understanding barriers and optimizing socio‐cognitive assessment in the diagnosis of neurocognitive disorders
  16. Analysis and interpretation of inflammatory fluid markers in Alzheimer’s disease: a roadmap for standardization
  17. Message From the Editors to Our Reviewers
  18. The problem of multiple adjustments in the assessment of minimal clinically important differences
  19. Biomarkers in Clinical Trials of Alzheimer Disease: An Overview
  20. Associations between selected genetic variants and lipid profile variability in response to statins in Alzheimer’s disease: a prospective observational study
  21. List of Reviewers
  22. Anthropometric and Demographic Features Affect the Interpretation of Cerebrospinal Fluid Biomarkers in Patients with Different Dementia Syndromes and Cognitively Healthy Adults
  23. Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
  24. Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
  25. Assessing Independence in Activities of Daily Living and Quality of Life in Patients with Dementia with Lewy Bodies
  26. Message From the Editors to Our Reviewers
  27. Shedding Light on the Effects of Blood Pressure on Cognitive Decline and Dementia Risk by Way of Neurobiological Evidence
  28. Biofluid Activity and Levels of the Angiotensin-converting Enzyme Are Surrogates for Diverse Cerebrospinal Fluid Amyloid-beta Effects in Dementia with Lewy Bodies and Alzheimer’s Dementia (P6-9.001)
  29. Message From the Editors to Our Reviewers
  30. Acknowledgement to Reviewers
  31. List of Reviewers
  32. GRIN2B genotypes and APOE haplotypes affect the age at onset of Alzheimer’s dementia as well as variations in dementia staging according to the use of Memantine
  33. Differential performance of cerebrospinal fluid biomarker ratios and formulas to discriminate dementia with Lewy bodies from Alzheimer’s dementia and cognitively healthy people reflects high level of amyloidosis across dementia syndromes
  34. Biofluid activity and levels of the angiotensin‐converting enzyme may translate into distinct neuropsychiatric symptoms associated with cerebrospinal fluid amyloid‐beta effects and tauopathy in dementia with Lewy bodies and Alzheimer’s dementia
  35. Disparities in neuropsychiatric symptom clusters across dementia diagnoses within Lewy body dementia syndromes and Alzheimer’s dementia
  36. Variations in metabolic risk factors for dementia do not affect APOE‐mediated cognitive or functional decline in patients with Alzheimer’s disease from São Paulo, Brazil
  37. Pitfalls and biases in neuroepidemiological studies of COVID-19 and the nervous system: a critical appraisal of the current evidence and future directions
  38. Pharmacogenetics of angiotensin modulators according to APOE-ε4 alleles and the ACE insertion/deletion polymorphism in Alzheimer’s disease
  39. Message From the Editors to Our Reviewers
  40. Looking Behind the Curtain: Patient Stratification According to Genetic or Demographic Factors May Yield Unexpected Results in Studies of Neurodegenerative Diseases
  41. Effects of the DICE Method to Improve Timely Recognition and Treatment of Neuropsychiatric Symptoms in Early Alzheimer’s Disease at the Memory Clinic: The BEAT-IT Study
  42. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer’s disease
  43. Lifestyle and pharmacological interventions in South America: Potential barriers for recruitment, implementation, and effectiveness
  44. Acknowledgement to Reviewers
  45. Message From the Editors to Our Reviewers
  46. List of Reviewers
  47. The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
  48. Acknowledgement to Referees
  49. Acknowledgement
  50. APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer’s Disease
  51. Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
  52. Message From the Editors to Our Reviewers
  53. Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer’s Disease
  54. New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
  55. The Viability of Treatment Conditioned to the Pathophysiology of Alzheimer’s Disease
  56. Vascular cognitive impairment and dementia: An early career researcher perspective
  57. Message From the Editors to Our Reviewers
  58. List of Reviewers
  59. Acknowledgement
  60. Reviewer Acknowledgement, 2021
  61. Message From the Editors to Our Reviewers
  62. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer’s Disease and Cognitively Healthy People
  63. Abstract Anne H Berman – incoming ISBM president
  64. Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer’s disease depend upon stratification according to APOE-ϵ4 carrier status
  65. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe
  66. APOE-ɛ4-mediated correlates of cerebrospinal fluid biomarkers of amyloidosis and neurodegeneration with cognition and functionality in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (49)
  67. Acknowledgements to Reviewers
  68. Swallowing in behavioral variant frontotemporal dementia
  69. Message From the Editors to Our Reviewers
  70. List of Reviewers
  71. Klüver‐Bucy syndrome due to stroke in the left temporal lobe
  72. Vascular cognitive impairment due to dilated perivascular spaces in putamen: Connections with the ventrolateral prefrontal cortex and neurological deficits
  73. Dementia in Latin America: Paving the way toward a regional action plan
  74. Correlates of neuropsychiatric and motor tests with language assessment in patients with Lewy body dementia
  75. Selected LDLR and APOE Polymorphisms Affect Cognitive and Functional Response to Lipophilic Statins in Alzheimer’s Disease
  76. Neuropsychiatric feature profiles of patients with Lewy body dementia
  77. Agitation and impulsivity in mid and late life as possible risk markers for incident dementia
  78. The impact of SARS‐CoV‐2 in dementia across Latin America: A call for an urgent regional plan and coordinated response
  79. Acknowledgments
  80. CEREBROSPINAL-FLUID-BASED BIOMARKER EVIDENCE OF AMYLOIDOGENESIS IN DEMENTIA WITH LEWY BODIES DEPENDS UPON APOE-ε4 CARRIER STATUS
  81. PRISON WITHOUT WALLS: A CASE REPORT OF SEMANTIC VARIANT PRIMARY PROGRESSIVE APHASIA
  82. GRIN2A GENOTYPES AND APOE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER’S DEMENTIA BUT NOT FUNCTIONAL OR COGNITIVE RESPONSE TO MEMANTINE
  83. FOOT CLEARANCE WHILE STEPPING-IN-PLACE AS A TOOL TO SALIENT COGNITIVE AND MOTOR OUTPUT DEFICITS IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A PRELIMINARY STUDY
  84. BEHAVIORAL CORRELATES OF CEREBROSPINAL FLUID BIOMARKERS ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  85. Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
  86. Acknowledgements to Reviewers
  87. Acknowledgments
  88. Influence of Socioeconomic Status and Stress Over Quality of Sleep: A Systematic Review
  89. Author Index
  90. Keyword Index
  91. Movement Disorders: Volume 33, Number S2, October 2018
  92. Abstracts
  93. Lifetime Risk Factors for Functional and Cognitive Outcomes in Patients with Alzheimer’s Disease
  94. GENETICALLY MEDIATED LIFETIME RISK FACTORS FOR COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS WITH ALZHEIMER’S DEMENTIA FROM SÃO PAULO, BRAZIL
  95. APOE-DEPENDENT PSYCHOTROPIC EFFECTS OVER CLINICAL CHANGES IN ALZHEIMER’S DISEASE DEMENTIA
  96. COGNITIVE AND FUNCTIONAL CORRELATES OF CEREBROSPINAL FLUID CONCENTRATIONS OF AMINOACIDS AND MONOAMINE METABOLITES ACCORDING TO APOE-ε4 CARRIER STATUS IN DEMENTIA WITH LEWY BODIES COMPARED WITH ALZHEIMER’S DEMENTIA AND COGNITIVELY HEALTHY PEOPLE
  97. COGNITIVE CHANGES ARE PHARMACOGENETICALLY MEDIATED BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH ALZHEIMER’S DISEASE DEMENTIA
  98. Behavioral correlates of cerebrospinal fluid concentrations of aminoacids and monoamine metabolites according to APOE-ɛ4 carrier status in dementia with Lewy bodies compared with Alzheimer’s dementia and cognitively healthy people (P4.190)
  99. Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
  100. Acknowledgement to reviewers
  101. Effects of APOE haplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer's disease
  102. Acknowledgements to Reviewers
  103. ePresentation
  104. ePoster Session
  105. Author Index
  106. Issue Information
  107. Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer’s disease dementia
  108. Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia
  109. Reviewers for International Journal of Stroke 2016
  110. Neurological impressions on the organization of language networks in the human brain
  111. GRIN1 GENOTYPES AND APOE GENE HAPLOTYPES AFFECT THE AGE AT ONSET OF ALZHEIMER'S DISEASE DEMENTIA BUT NOT COGNITIVE OR FUNCTIONAL RESPONSE TO MEMANTINE
  112. EFFECTS OF APOE GENE HAPLOTYPES AND MEASURES OF CARDIOVASCULAR RISK OVER COGNITIVE AND FUNCTIONAL DECLINE IN ONE YEAR IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA
  113. MOTOR ASPECTS OF DAILY LIVING FOLLOW COGNITIVE AND FUNCTIONAL STATUS BUT NOT BEHAVIOURAL SYMPTOMS IN PATIENTS WITH LEWY BODY DEMENTIA SYNDROMES
  114. Balance impairment does not necessarily coexist with gait apraxia in mild and moderate Alzheimer’s disease
  115. Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease
  116. Swallowing in primary progressive aphasia
  117. Predictors of Cognitive and Functional Decline in Patients With Alzheimer Disease Dementia From Brazil
  118. Associations of Blood Pressure with Functional and Cognitive Changes in Patients with Alzheimer's Disease
  119. The Controversial Influence of Cerebrovascular Risk Factors over Pathological Mechanisms of Late-Onset Alzheimer's Disease Dementia
  120. Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil
  121. Correlations among cognitive and behavioural assessments in patients with dementia due to Alzheimer's disease
  122. Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-ε3/ε3 Patients With Late-onset Alzheimer Disease Dementia
  123. A patient with agrammatic primary progressive aphasia developing frontotemporal dementia
  124. Pharmacogenetics of cerebrovascular metabolism modulators in dementia due to Alzheimer’s disease
  125. Assessment of sleep satisfaction in patients with dementia due to Alzheimer’s disease
  126. Acknowledgements
  127. Is there correlation between cognition and functionality in severe dementia? The value of a performance-based ecological assessment for Alzheimer’s disease
  128. Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia due to Alzheimer's Disease
  129. P2‐024: PHARMACOGENETICS OF BRAIN‐PENETRATING ANGIOTENSIN‐CONVERTING ENZYME INHIBITORS IN DEMENTIA DUE TO ALZHEIMER'S DISEASE
  130. P2‐025: PHARMACOGENETICS OF CHOLESTEROL‐LOWERING DRUGS IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE
  131. P3‐333: RISK FACTORS FOR COGNITIVE CHANGE IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE FROM SÃO PAULO, BRAZIL
  132. Caregiver awareness of cerebrovascular risk of patients with dementia due to Alzheimer's disease in São Paulo, Brazil
  133. Abstracts from the 29th CINP World Congress of Neuropsychopharmacology, Vancouver, Canada, 22–26 June 2014
  134. Risk Factors for Cognitive Change in Patients with Dementia Due to Alzheimer’s Disease (P5.210)
  135. Pharmacogenetics of Lipid Metabolism Modulators in Patients with Dementia Due to Alzheimer’s Disease (P5.223)
  136. Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from São Paulo, Brazil
  137. 2013 Reviewer Acknowledgement
  138. Assessment of risk factors for earlier onset of sporadic Alzheimer′s disease dementia
  139. Educational bias in the assessment of severe dementia: Brazilian cutoffs for severe Mini-Mental State Examination
  140. Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease
  141. Cognitive Impairment in Fibromyalgia
  142. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (IN6-1.009)
  143. Impact of Cardiovascular Risk over the Rate of Progression of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from São Paulo, Brazil (P07.136)
  144. Communicating with the non-dominant hemisphere: Implications for neurological rehabilitation
  145. Normal pressure hydrocephalus in the spectrum of neurological complications of systemic lupus erythematosus
  146. A patient with primary progressive aphasia developing dementia due to Alzheimer's disease
  147. Impact of Cerebrovascular Risk Factors over Age of Onset of Dementia Due to Alzheimer's Disease in a Sample of Patients with Low Schooling from Sao Paulo, Brazil (P04.201)
  148. 2012 Annual Meeting Sunday, October 7, 2012 Poster Session Abstracts
  149. A topographic study on the evaluation of speech and language in the acute phase of a first stroke
  150. P1‐453: Functional independence and tests of cognitive assessment in patients with Alzheimer's disease
  151. P2‐153: Impact of cardiovascular risk factors over age of Alzheimer's disease onset in patients with low schooling
  152. P3‐260: Impact of schooling and cardiovascular risk factors over the rate of progression of Alzheimer's disease
  153. Twenty-first Meeting of the European Neurological Society 28–31 May, 2011
  154. Global aphasia as a predictor of mortality in the acute phase of a first stroke
  155. Semantic aphasia as a sole manifestation of acute stroke
  156. Preliminary topographic diagnosis of ischemic brain injuries according to speech and language disorders
  157. Short-term prognosis for speech and language in first stroke patients
  158. Hypoglossal nerve palsy as the sole manifestation of spontaneous internal carotid artery dissection
  159. Author Index
  160. Abstracts
  161. 0661 Primitive Neuroectodermal Tumor of the brain presenting with late spinal cord dissemination after surgical treatment and complementary radiotherapy and chemotherapy
  162. 1499 Trends on the use of complementary exams in modern day neurology: how to teach the patient about the tools actually needed for the investigation without conflicting knowledge with popular wisdom